Loading...

Ralph W deVere White

TitleProf
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM. Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther. 2018 Jun; 365(3):494-506. PMID: 29602831.
      View in: PubMed
    2. Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White R, Pan CX, Li Y. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine. 2018 Apr; 14(3):789-799. PMID: 29317342.
      View in: PubMed
    3. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White R, Pan CX. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6580-6591. PMID: 28808038.
      View in: PubMed
    4. Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget. 2017 May 09; 8(19):30742-30755. PMID: 28415566.
      View in: PubMed
    5. Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White R, Yap SA. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder Cancer. 2016 Oct 27; 2(4):441-448. PMID: 28035325.
      View in: PubMed
    6. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. PMID: 27640312.
      View in: PubMed
    7. Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 2016 10; 104:339-51. PMID: 27479049.
      View in: PubMed
    8. Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R. Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol. 2016 Nov; 196(5):1378-1382. PMID: 27208515.
      View in: PubMed
    9. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. PMID: 27019001; PMCID: PMC4892938 [Available on 06/15/17].
    10. Vinall RL, Tepper CG, Ripoll AA, Gandour-Edwards RF, Durbin-Johnson BP, Yap SA, Ghosh PM, deVere White R. Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer. 2016 Mar; 7(3-4):86-97. PMID: 27382433; PMCID: PMC4918947.
    11. Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White R. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res. 2015 Dec 15; 75(24):5309-17. PMID: 26573802.
      View in: PubMed
    12. Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White R, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015 Jan; 193(1):19-29. PMID: 25158272; PMCID: PMC4405894.
    13. Hackman RM, Aggarwal BB, Applebaum RS, deVere White R, Dubick MA, Heber D, Ito T, Johnson GH, Keen CL, Winters BL, Stohs SJ. Forecasting nutrition research in 2020. J Am Coll Nutr. 2014; 33(4):340-6. PMID: 25144361.
      View in: PubMed
    14. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. PMID: 24258693.
      View in: PubMed
    15. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One. 2013; 8(4):e61064. PMID: 23585871; PMCID: PMC3621663.
    16. Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer. 2012 Dec; 19(6):759-77. PMID: 22993077; PMCID: PMC3540117.
    17. deVere White R. An interview with Ralph W. deVere White. Interview by John Fitzpatrick. BJU Int. 2012 Nov; 110(9):1221-2. PMID: 23066713.
      View in: PubMed
    18. Vinall RL, Kent MS, deVere White R. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Am J Vet Res. 2012 Oct; 73(10):1626-33. PMID: 23013190.
      View in: PubMed
    19. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White R, Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013 Mar; 73(4):418-27. PMID: 22996738; PMCID: PMC3938015.
    20. Vinall RL, Chen JQ, Hubbard NE, Sulaimon SS, Shen MM, Devere White RW, Borowsky AD. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression. Dis Model Mech. 2012 Nov; 5(6):914-20. PMID: 22563073; PMCID: PMC3484872.
    21. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White R, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012; 7(3):e32832. PMID: 22479342; PMCID: PMC3316551.
    22. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7. PMID: 22386416; PMCID: PMC3839235.
    23. Jacobson MC, deVere White R, Demos SG. In vivo testing of a prototype system providing simultaneous white light and near infrared autofluorescence image acquisition for detection of bladder cancer. J Biomed Opt. 2012 Mar; 17(3):036011. PMID: 22502569.
      View in: PubMed
    24. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White R. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 2012 Jun 01; 130(11):2526-38. PMID: 21702042; PMCID: PMC4568996.
    25. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White R, Ghosh PM. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011 Oct 01; 17(19):6218-28. PMID: 21844010; PMCID: PMC3186857.
    26. Shi XB, Xue L, Shi D, deVere White R. Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor. Cancer Biother Radiopharm. 2011 Apr; 26(2):191-201. PMID: 21539451; PMCID: PMC3128791.
    27. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN, Devere White RW. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15; 117(18):4219-30. PMID: 21412759.
      View in: PubMed
    28. Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL, Ghosh PM. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res. 2010 Jul 15; 70(14):5994-6003. PMID: 20587519; PMCID: PMC2905475.
    29. deVere White R, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer. 2010; 62(8):1036-43. PMID: 21058191; PMCID: PMC2993162.
    30. Hellenthal NJ, Ramirez ML, Evans CP, Devere White RW. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy. BJU Int. 2010 Feb; 105(4):485-8. PMID: 19849694.
      View in: PubMed
    31. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009 Sep 15; 115(18):4096-103. PMID: 19536899.
      View in: PubMed
    32. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol. 2009 May-Jun; 27(3):307-11. PMID: 19414119; PMCID: PMC2761743.
    33. deVere White R, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MH, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun; 181(6):2476-80; discussion 2480-1. PMID: 19371909.
      View in: PubMed
    34. Hellenthal NJ, Ramírez ML, Evans CP, deVere White R, Koppie TM. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol. 2009 Jun; 181(6):2490-5. PMID: 19371902.
      View in: PubMed
    35. deVere White R, Katz MH, Steinberg GD. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer. J Urol. 2009 May; 181(5):1994-7. PMID: 19286209.
      View in: PubMed
    36. Hellenthal NJ, Chamie K, Ramirez ML, deVere White R. Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 2009 Mar; 181(3):1013-8; discussion 1018-9. PMID: 19150554.
      View in: PubMed
    37. Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White R. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. Prostate. 2008 Dec 01; 68(16):1816-26. PMID: 18780293.
      View in: PubMed
    38. Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer. 2008 Nov 01; 113(9):2464-70. PMID: 18666213.
      View in: PubMed
    39. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, deVere White R. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res. 2008 May; 6(5):808-18. PMID: 18505925.
      View in: PubMed
    40. Ramírez ML, Nelson EC, Devere White RW, Lara PN, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol. 2008 Aug; 54(2):291-300. PMID: 18439749.
      View in: PubMed
    41. Chamie K, Hu B, Devere White RW, Ellison LM. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int. 2008 Aug; 102(3):284-90. PMID: 18410437.
      View in: PubMed
    42. Shi XB, Tepper CG, deVere White R. Cancerous miRNAs and their regulation. Cell Cycle. 2008 Jun 01; 7(11):1529-38. PMID: 18469525.
      View in: PubMed
    43. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White R. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19983-8. PMID: 18056640; PMCID: PMC2148409.
    44. Mudryj M, Reay E, Beckett L, Dandekar S, deVere White R, Gandour-Edwards R. Novel p53/p130 axis in bladder tumors. Urology. 2007 Sep; 70(3):608-12. PMID: 17905135.
      View in: PubMed
    45. Cambio AJ, Ellison LM, Chamie K, deVere White R, Evans CP. Cost-benefit and outcome analysis: effect of prostate biopsy undergrading. Urology. 2007 Jun; 69(6):1152-6. PMID: 17572205.
      View in: PubMed
    46. Shi XB, Xue L, Tepper CG, Gandour-Edwards R, Ghosh P, Kung HJ, DeVere White RW. The oncogenic potential of a prostate cancer-derived androgen receptor mutant. Prostate. 2007 May 01; 67(6):591-602. PMID: 17262801.
      View in: PubMed
    47. Liao YC, Si L, deVere White R, Lo SH. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 2007 Jan 01; 176(1):43-9. PMID: 17190795; PMCID: PMC2063623.
    48. Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White R, Kung HJ, Chen H. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate. 2006 Oct 01; 66(14):1474-86. PMID: 16921507.
      View in: PubMed
    49. Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, Shih HM, Shi XB, deVere White R, Chen HW, Tepper CG, Kung HJ. Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. Cancer Res. 2006 Sep 01; 66(17):8439-47. PMID: 16951154.
      View in: PubMed
    50. Devere White RW. Transurethral resection of superficial bladder cancer using 5-aminolevulinic acid: are there any long-term benefits? Nat Clin Pract Urol. 2006 May; 3(5):254-5. PMID: 16691236.
      View in: PubMed
    51. Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White R. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate. 2005 Dec 01; 65(4):375-89. PMID: 16037992.
      View in: PubMed
    52. Karpman E, Goldberg Z, Saffarian A, Gandour-Edwards R, Ellison LM, deVere White R. Analysis of treatment for small cell cancer of the bladder and report of three cases. Urology. 2004 Sep; 64(3):494-8. PMID: 15351578.
      View in: PubMed
    53. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White R. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate. 2004 Aug 01; 60(3):257-71. PMID: 15176055.
      View in: PubMed
    54. Demos SG, Gandour-Edwards R, Ramsamooj R, deVere White R. Spectroscopic detection of bladder cancer using near-infrared imaging techniques. J Biomed Opt. 2004 Jul-Aug; 9(4):767-71. PMID: 15250764.
      View in: PubMed
    55. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004 Jul 15; 22(14):2781-9. PMID: 15199091.
      View in: PubMed
    56. Madewell BR, Gandour-Edwards R, DeVere White RW. Canine prostatic intraepithelial neoplasia: is the comparative model relevant? Prostate. 2004 Feb 15; 58(3):314-7. PMID: 14743472.
      View in: PubMed
    57. deVere White R, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology. 2004 Feb; 63(2):259-63. PMID: 14972467.
      View in: PubMed
    58. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White R, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28; 349(9):859-66. PMID: 12944571.
      View in: PubMed
    59. Nesslinger NJ, Shi XB, deVere White R. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res. 2003 May 01; 63(9):2228-33. PMID: 12727844.
      View in: PubMed
    60. Highshaw RA, Tanaka ST, Evans CP, deVere White R. Is bladder biopsy necessary at three or six months post BCG therapy? Urol Oncol. 2003 May-Jun; 21(3):207-9. PMID: 12810207.
      View in: PubMed
    61. Scott SL, Higdon R, Beckett L, Shi XB, deVere White R, Earle JD, Gumerlock PH. BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm. 2002 Dec; 17(6):647-56. PMID: 12537668.
      View in: PubMed
    62. Shi XB, Di Mauro SM, Highshaw R, Deitch AD, Evans CP, Gumerlock PH, deVere White R. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother Radiopharm. 2002 Dec; 17(6):657-64. PMID: 12537669.
      View in: PubMed
    63. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002 Nov; 168(5):2016-9. PMID: 12394698.
      View in: PubMed
    64. deVere White R, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology. 2002 Oct; 60(4):640-4. PMID: 12385925.
      View in: PubMed
    65. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White R. Complex functions of mutant p53 alleles from human prostate cancer. Prostate. 2002 Apr 01; 51(1):59-72. PMID: 11920959.
      View in: PubMed